RUA Life Sciences, a holding company for medical device businesses, released a trading update for the 12-month period ending March 31, 2025. The Groups strategic focus has been on growing its contract manufacturing business and exploiting its IP, resulting in significant revenue growth from £2.2m to £4.1m. This includes a 19% increase in biomaterials royalties and a 106% increase in medical devices and components revenue. Costs were well-controlled, with a 22% reduction in like-for-like costs, and cash utilization was significantly reduced. The Group expects to report positive EBITDA of c£0.3m compared to a loss in the previous period. The outlook for the Group remains positive, with opportunities in contract manufacturing, potential new licenses for Elast-Eon, and interest in AurTex for heart valve use. The full unaudited accounts for the 12-month period are expected to be published in mid-June 2025, followed by audited accounts for the 18-month period ending September 30, 2025, by the end of January 2026.